|
1.
Bradley TR and Metcalf D. The growth of mouse bone marrow cells in vitro.
Aust. J. Exp. Biol. Med. 1966; 44: 287-300. 2. Ichikawa Y et al. In
vitro control of the development of macrophage and granulocyte colonies.
Proc. Natl. Acad. Sci. USA 1966; 56: 488-495. 3. Metcalf D. The Hemopoietic
Colony Stimulating Factors. Amsterdam: Elsevier, 1984. 4. Metcalf
D and Nicola NA. The hemopoietic colony stimulating factors. London:
Cambridge University Press, 1995. 5. Metcalf D and Nicola NA. Direct
proliferative actions of stem cell factor on murine bone marrow cells
in vitro: effects of combination with colony-stimulating factors.
Proc. Natl. Acad. Sci. USA 1991; 88: 6239-6243. 6. McKinstry W et
al. Distribution of IL-6 receptors on murine hemopoietic and lymphoid
cells and the anomalous action of IL-6 in stimulating granulocytic
proliferation. Leukemia 1994; 8: 1726-1733. 7. Metcalf D et al. In
vitro actions on hemopoietic cells of recombinant murine GM-CSF purified
after production in Escherichia coli: Comparison with purified native
GM-CSF. J.Cell. Physiol. 1986; 128: 421-431. 8. Metcalf D et al. The
regulation of hematopoiesis in max 41 transgenic mice with sustained
excess granulopoiesis. Leukemia 1996; 10: 311-320. 9. Metcalf D and
Nicola NA. Proliferative effects of purified granulocyte colony-stimulating
factor (G-CSF) on normal mouse hematopoietic cells. J. Cell. Physiol.
1983; 116: 198-206. 10. Metcalf D et al. Quantitative responsiveness
of murine hemopoietic populations in vitro and in vivo to recombinant
Multi-CSF (IL-3). Exp. Hematol. 1987; 15: 288-295. 11. Metcalf D and
Nicola NA. The clonal proliferation of normal mouse hemopoietic cells:
Enhancement and suppression by CSF combinations. Blood 1992; 79: 2861-2866.
12. Metcalf D. Clonal analysis of proliferation and differentiation
of paired daughter cells: Action of granulocyte-macrophage colony-stimulating
factor on granulocyte-macrophage precursors. Proc. Natl. Acad. Sci.
USA 1980; 77: 5327-5330. 13. Metcalf D and Merchav S. Effects of GM-CSF
deprivation on precursors of granulocytes and macrophages. J. Cell.
Physiol. 1982; 112: 411-418. 14. Begley CG et al. Purified colony
stimulating factor enhance the survival of human neutrophils and eosinophils
in vitro: a rapid and sensitive microassay for colony stimulating
factors. Blood 1986; 68: 162-166. 15. Williams GT et al. Haemopoietic
colony stimulating factors promote cell survival by suppressing apoptosis.
Nature (London) 1990; 343: 76-79. 16. Metcalf D et al. Clonal analysis
of progenitor cell commitment to granulocyte or macrophage production.
J. Cell. Physiol. 1982; 111: 275-282. 17. Valtieri M et al. Cytokine-dependent
granulocytic differentiation: Regulation of proliferative and differentiative
responses in a murine progenitor cell line. J. Immunol. 1987; 138:
3829-3835. 18. Grant SM and Heel RC. Recombinant granulocyte-macrophage
colony-stimulating factor (rGM-CSF). Drugs 1992; 43: 516-560. 19.
Hollingshead LM and Goa RL. Recombinant granulocyte colony-stimulating
factor (rG-CSF). A review of its pharmacological properties and prospective
role in neutropenic conditions. Drugs 1991; 42: 300-330. 20. Metcalf
D et al. Production of hematopoietic regulatory factors in cultures
of adult and fetal mouse organs: Measurement by specific bioassays.
Leukemia 1995; 9: 1556-1564. 21. Layton JE et al. Evidence for a novel
in vivo control mechanism of granulopoiesis: Mature cell-related control
of a regulatory growth factor. Blood 1989; 74: 1303-1307. 22. Metcalf
D et al. Effects of purified bacterially synthesized murine Multi-CSF
(IL-3) on hematopoiesis in normal adult mice. Blood 1986; 68: 46-57.
23. Metcalf D et al. Hemopoietic responses in mice injected with purified
recombinant murine GM-CSF. Exp. Hematol. 1987; 15: 1-9. 24. Molineux
G et al. A comparison of hematopoiesis in normal and splenectomized
mice treated with granulocyte colony-stimulating factor. Blood 1990;
75: 563-569. 25. Cole DJ et al. Phase I trial of recombinant human
macrophage colony-stimulating factor administered by continuous intravenous
infusion in patients with metastatic cancer. J. Natl. Cancer Instit.
1994; 86: 39-45. 26. Lord BI et al. Myeloid cell kinetics in mice
treated with recombinant interleukin-3, granulocyte colony-stimulating
(CSF), or granulocyte-macrophage CSF in vivo. Blood 1991; 77: 2154-2159.
27. de Haan G et al. Long-term recombinant human granulocyte colony-stimulating
factor (rhG-CSF) treatment severely depresses murine marrow erythropoiesis
without causing an anemia. Exp. Hematol. 1992; 20: 600-604. 28. Roberts
AW and Metcalf D. Granulocyte colony-stimulating factor induces selective
elevations of progenitor cells in the peripheral blood of mice. Exp.
Hematol. 1994; 22: 1156-1163. 29. Cynshi O et al. Reduced response
to granulocyte colony-stimulating factor in W/Wv and Sl/Sld mice.
Leukemia 1991; 5: 75-77. 30. Postmus RE et al. Effects of recombinant
interleukin-3 in patients with relapsed small-cell lung cancer treated
with chemotherapy: A dose-finding study. J. Clin. Oncol. 1992; 10:
1131-1140. 31. Dührsen U et al. Effects of recombinant human granulocyte
colony-stimulating factor on hemopoietic progenitor cells in cancer
patients. Blood 1998; 72: 2074-2081. 32. Socinski MA et al. Granulocyte-macrophage
colony-stimulating factor expands the circulating haemopoietic progenitor
cell compartment in man. Lancet 1988; 1: 1194-1198. 33. Molineux G
et al. Transplantation potential of peripheral blood stem cells induced
by granulocyte colony-stimulating factor. Blood 1990; 76: 2153-2158.
34. Roberts AW et al. Genetic influences determining progenitor cell
mobilization and leukocytosis induced by granulocyte colony-stimulating
factor. Blood 1997; 89: 2736-2744. 35. Sheridan WP et al. Effect of
peripheral-blood progenitor cells mobilized by Filgrastim (G-CSF)
on platelet recovery after high-dose chemotherapy. Lancet 1992; 339:
640-644. 36. Matsumoto M et al. Protective effect of human granulocyte
colony-stimulating factor on microbial infection in neutropenic mice.
Infect. Immun. 1987; 55: 2715-2720. 37. Yasuda H et al. Therapeutic
efficacy of granulocyte colony-stimulating factor alone and in combination
with antibiotics against Pseudomonas aeruginosa infections in mice.
Infect. Immun. 1990; 58: 2502-2509. 38. Cairo MS et al. Prophylactic
or simultaneous administration of recombinant human granulocyte colony
stimulating factor in the treatment of group B streptococcal sepsis
in neonatal rats. Pediatr. Res. 1990; 27: 612-616. 39. Metcalf D et
al. Role of granulocyte-macrophage colony-stimulating factor and granulocyte
colony-stimulating factor in the development of an acute neutrophil
inflammatory response in mice. Blood 1996; 88: 3755-3764. 40. Sherr
CJ et al. Colony-stimulating factor-1 receptor. Blood 1990; 75: 1-12.
41. Fukunaga R et al. Purification and characterization of the receptor
for murine granulocyte colony-stimulating factor. J. Biol. Chem. 1990;
265: 14008-14015. 42. Gearing DP et al. Expression cloning of a receptor
for human granulocyte-macrophage colony-stimulating factor. EMBO J.
1989; 8: 3667-3676. 43. Kitamura T et al. Expression of the human
IL-3 receptor cDNA reveals a shared beta subunit for the human IL-3
and GM-CSF receptors. Cell 1991; 66: 1165-1174. 44. Tavernier J et
al. A human high affinity interleukin-5 receptor (IL5R) is composed
of an IL5-specific alpha chain and a beta chain shared with the receptor
for GM-CSF. Cell 1991; 66: 1175-1184. 45. Fukunaga R et al. Growth
and differentiation signals mediated by different regions in the cytoplasmic
domain of granulocyte-stimulating factor receptor. Cell 1993; 74:
1079-1087. 46. Smith et al. Cytoplasmic domains of the common beta-chain
of the GM-CSF/IL-3/IL-5 receptors that are required for inducing differentiation
or clonal suppression in myeloid leukaemic cell lines. EMBO J. 1997;
16: 451-464. 47. McArthur GA et al. Induced expression of c-fms in
normal hematopoietic cells shows evidence for both conservation and
lineage restriction of signal transduction in response to macrophage
colony-stimulating factor. Blood 1994; 83: 972-981. 48. Rohrschneider
LR and Metcalf D. Induction of macrophage colony-stimulating factor-dependent
growth and differentiation after introduction of the murine c-fms
gene into FDC-P1 cells. Mol. Cell. Biol. 1989; 9: 5081-5092. 49. Evans
CA et al. Activation of granulocyte-macrophage colony-stimulating
factor and interleukin-3 receptor subunits in a multipotential hematopoietic
progenitor cell line leads to differential effects on development.
Blood 1999; 94: 1504-1514. 50. Fairburn LJ et al. Suppression of apoptosis
allows differentiation and development of a multipotent hemopoietic
cell line in the absence of added growth factors. Cell 1993; 74: 823-832.
51. Lieschke GJ et al. Mice lacking granulocyte colony-stimulating
factor have chronic neutropenia, granulocyte and macrophage progenitor
cell deficiency, and impaired neutrophil mobilization. Blood 1994;
84: 1737-1746. 52. Yoshida H et al. The murine mutation osteopetrosis
is in the coding region of the macrophage colony stimulating factor
gene. Nature 1990; 345: 442-444. 53. Wiktor-Jedrzejczak W et al. CSF-1
deficiency in the op/op mouse has differential effects on macrophage
populations and differentiation stages. Exp. Hematol. 1992; 20: 1004-1010.
54. Stanley E et al. Granulocyte/macrophage colony-stimulating factor-deficient
mice show no major perturbation of hematopoiesis but develop a characteristic
pulmonary pathology. Proc. Natl. Acad. Sci. USA 1994; 91: 5592-5596.
55. Dranoff G et al. Involvement of granulocyte-macrophage colony-stimulating
factor in pulmonary homeostasis. Science 1994; 264: 713-716. 56. Seymour
JF et al. Mice lacking both granulocyte colony-stimulating factor
(CSF) and granulocyte-macrophage CSF have impaired reproductive capacity,
perturbed neonatal granulopoiesis, lung disease, amyloidosis, and
reduced long-term survival. Blood 1997; 15: 3037-3049. 57. Mach N
et al. Involvement of interleukin-3 in delayed-type hypersensitivity.
Blood 1998; 91: 778-783. 58. Ruscetti FW et al. Reduced blood and
marrow neutrophils and granulocytic colony-forming cells in Sl/Sld
mice. Proc. Soc. Exp. Biol. Med. 1976; 152: 398-402. 59. Lang RA et
al. Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF)
develop accumulations of macrophages, blindness and a fatal syndrome
of tissue damage. Cell 1987; 51: 675-686. 60. Metcalf D and Moore
JG. Divergent disease patterns in GM-CSF transgenic mice associated
with differing transgene insertion sites. Proc. Natl. Acad. Sci. USA
1988; 85: 7767-7771. 61. Chang JM et al. Non-neoplastic hematopoietic
myeloproliferative syndrome induced by dysregulated Multi-CSF (IL-3)
expression. Blood 1989; 73: 1487-1497. 62. Welte K et al. Filgrastim
(r-metHuG-CSF): The first 10 years. Blood 1996; 88: 1907-1929. 63.
Armitage JO. Emerging applications of recombinant human granulocyte-macrophage
colony-stimulating factor. Blood 1998; 92: 4491-4508. 64. Dale DC
et al. Randomized controlled Phase III trial of recombinant human
granulocyte colony-stimulating factor (Filgrastim) for treatment of
severe chronic neutropenia. Blood 1993; 81: 2496-2502. 65. Körbling
M. Peripheral blood stem cells for allogeneic transplantation. In
Hematopoietic Cell Transplantation. Thomas ED, Blume KG, Forman SJ
eds. Blackwell Science Malden MA, 1994; 469-480. 66. Inaba K et al.
Generation of large numbers of dendritic cells from mouse bone marrow
cultures supplemented with granulocyte/macrophage colony-stimulating
factor. J. Exp. Med. 1992; 176: 1693-1702. 67. Murray PJ et al. Manipulation
and potentiation of antimycobacterial immunity using recombinant bacille
Calmette-Guerin strains that secrete cytokines. Proc. Natl. Acad.
Sci. USA 1996; 93: 934-939. 68. Caspar CB et al. Idiotype vaccines
for non-Hodgkin’s lymphoma induce polyclonal immune responses that
cover mutated tumor idiotypes: comparison of different vaccine formulations.
Blood 1997; 90: 3699-3706.
|
